Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.98 |
| ▸ | HPGD | P15428 | 5/20 | 0.98 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.98 |
| ▸ | ALB | P02768 | 1/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.55 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | TUBB | P07437 | 1/20 | 0.54 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.54 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.54 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.54 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.54 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.54 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.54 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.54 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.54 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rufloxacin SCHEMBL23282883 | 0.99 | KDM4E (0.98) | KDM4EADRA2BMAPK1ALDH1A1HPGD | |
| Rufloxacin SCHEMBL8385662 | 0.99 | KDM4E (1.00) | KDM4EADRA2BMAPK1ALDH1A1HPGD | |
| Rufloxacin SCHEMBL8126704 | 0.99 | KDM4E (1.00) | KDM4EADRA2BMAPK1ALDH1A1HPGD | |
| Rufloxacin SCHEMBL8390373 | 0.99 | KDM4E (1.00) | KDM4EADRA2BMAPK1ALDH1A1HPGD | |
| Rufloxacin SCHEMBL51616 | 0.99 | KDM4E (1.00) | KDM4EADRA2BMAPK1ALDH1A1HPGD | |
| Rufloxacin SCHEMBL12505914 | 0.98 | KDM4E (0.98) | KDM4EADRA2BMAPK1ALDH1A1HPGD | |
| Rufloxacin SCHEMBL1651162 | 0.98 | KDM4E (0.96) | KDM4EADRA2BMAPK1ALDH1A1HPGD | |
| Rufloxacin SCHEMBL574492 | 0.98 | KDM4E (0.98) | KDM4EADRA2BMAPK1ALDH1A1HPGD | |
| Rufloxacin SCHEMBL838925 | 0.98 | KDM4E (0.98) | KDM4EADRA2BMAPK1ALDH1A1HPGD | |
| Rufloxacin SCHEMBL23581496 | 0.97 | KDM4E (0.96) | KDM4EADRA2BMAPK1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4113 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624057-B2 | Bisphosphonate quinolone conjugates and uses thereof | BIOVINC, LLC (US) | 2026-05-12 | — | — | US | claimed |
| US-20260090584-A1 | SYSTEMS AND METHODS FOR ESTIMATING AEROSOLIZATION EMISSION | SCIENTIFIC HORIZONS CONSULTING LLC (US) | 2026-04-02 | — | — | US | claimed |
| EP-4603146-A2 | COMBINATION OF ZIDOVUDINE AND FLUOROQUINOLONE ANTIBIOTIC | Helperby Therapeutics Limited (GB) | 2025-08-20 | — | — | EP | claimed |
| EP-4590371-A2 | SYSTEMS AND METHODS FOR ESTIMATING AEROSOLIZATION EMISSION | Scientific Horizons consulting LLC (US) | 2025-07-30 | — | — | EP | claimed |
| EP-4028022-B1 | COMBINATION OF ZIDOVUDINE AND FLUOROQUINOLONE ANTIBIOTIC | HELPERBY THERAPEUTICS LTD (GB) | 2025-07-09 | — | — | EP | claimed |
| EP-4554627-A1 | INHALABLE FORMULATION FOR USE IN THE TREATMENT OF BACTERIAL LUNG INFECTIONS | Solmic Biotech GmbH (DE) | 2025-05-21 | — | — | EP | claimed |
| EP-4554939-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | Astrazeneca AB (SE) | 2025-05-21 | — | — | EP | claimed |
| US-20250144088-A1 | INHALABLE FORMULATION FOR USE IN THE TREATMENT OF BACTERIAL LUNG INFECTIONS | Solmic Biotech GmbH (DE) | 2025-05-08 | — | — | US | claimed |
| WO-2025080590-A1 | CO-CRYSTALLIZATION OF ACTIVES WITH SACCHARIDE-BASED MOLECULAR FRAMEWORKS | SCIENTIFIC HORIZONS CONSULTING LLC (US) | 2025-04-17 | — | — | WO | claimed |
| US-12274830-B2 | Nitric oxide inhalation therapy for infants with bronchiolitis | BEYOND AIR LTD (IL) | 2025-04-15 | — | — | US | claimed |
| US-5703233-A | Quinilone disulfide as intermediates | ARCHIMICA SPA (IT) | 1997-12-30 | — | — | US | claimed |
| EP-0725785-B1 | PROCESS FOR THE PREPARATION OF RUFLOXACIN AND SALTS THEREOF | ARCHIMICA SPA (IT) | 1997-07-23 | — | — | EP | claimed |
| WO-1997024128-A1 | OTIC MICROBIAL COMBINATIONS | BAYER CORPORATION (US) | 1997-07-10 | — | — | WO | claimed |
| EP-0725785-A1 | PROCESS FOR THE PREPARATION OF RUFLOXACIN AND SALTS THEREOF | ARCHIMICA SPA (IT) | 1996-08-14 | — | — | EP | claimed |
| US-5532239-A | FOR THE TREATMENT OF NEPHROTIC SYNDROMES | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (FR) | 1996-07-02 | — | — | US | claimed |
| EP-0675880-A1 | QUINILONE DISULFIDE AS INTERMEDIATES | ARCHIMICA S.P.A. (IT) | 1995-10-11 | — | — | EP | claimed |
| WO-1995011907-A1 | PROCESS FOR THE PREPARATION OF RUFLOXACIN AND SALTS THEREOF | ARCHIMICA S.P.A. (IT) | 1995-05-04 | — | — | WO | claimed |
| WO-1995011886-A1 | QUINILONE DISULFIDE AS INTERMEDIATES | ARCHIMICA S.P.A. (IT) | 1995-05-04 | — | — | WO | claimed |
| US-5221741-A | Process for the preparation of 9-fluoro-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzothiazine-6-carboxylic acid hydrochloride | MEDIOLANUM FARMACEUTICI S.P.A. (IT) | 1993-06-22 | — | — | US | claimed |
| EP-0522277-A1 | Process for the preparation of 9-fluoro-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzothiazine-6-carboxylic acid hydrochloride | MEDIOLANUM FARMACEUTICI s.r.l. (IT) | 1993-01-13 | — | — | EP | claimed |